FDA Approve New NNRTI-Based Fixed-Dose Combination of Rilpivirine/Tenofovir/FTC (Complera) in the U.S.

From HIV i-Base

July/August 2011

On 10 August 2011, U.S. Food and Drug Administration (FDA) approved a fixed-dose combination of rilpivirine/tenofovir/FTC (Complera) with an indication in treatment-naive adults. This is a single-tablet once-daily combination.

Approval was based on bioequivilence to the individual drugs taken separately, together with the phase 3 registrational studies for rilpivirine (ECHO and THRIVE) -- see FDA approve rilpivirine in the U.S..

References

U.S. Food and Drug Administration approves Gilead sciences' Complera, a new complete once-daily, single-tablet regimen for HIV-1 infection in treatment-naive adults. Gilead press release. (10 August 2011).
Prescribing information.

Links to external websites are current at time of posting but not maintained.

Complera, My New 1-Pill-a-Day Regimen (and My Rosacea Diagnosis)

FDA Approves the New Full-Regimen HIV Pill Complera

This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.

More News & Research on Complera (Rilpivirine/Tenofovir/FTC)

Read Comments [1]

Add Your Comment:

(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

More News & Research on Complera (Rilpivirine/Tenofovir/FTC)

Newly Diagnosed? Words of Encouragement from HIV-Positive Women

HIV Management Today: Mental Health & HIV, the Uncharted Territory

Curing HIV Removes the Scars of the Past

Meth Makes an Ominous Comeback Among Gay Men

Can HIV-Positive People Have Babies? 7 Myths About Pregnancy and HIV/AIDS

More >>

TheBody.com App for iPhones

My Health Tracker

Medication and Health Reminders

Assess Your Risk for HIV

U.S. ASO Finder

The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.